Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic Risk Score: Results From the FOURIER Trial

BACKGROUND: The ability of a genetic risk score to predict risk in established cardiovascular disease and identify individuals who derive greater benefit from PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibition has not been established. METHODS: We studied 14 298 patients with atheroscl...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Circulation
Glavni autori: Marston, Nicholas A., Kamanu, Frederick K., Nordio, Francesco, Gurmu, Yared, Roselli, Carolina, Sever, Peter S., Pedersen, Terje R., Keech, Anthony C., Wang, Huei, Pineda, Armando Lira, Giugliano, Robert P., Lubitz, Steven A., Ellinor, Patrick T., Sabatine, Marc S., Ruff, Christian T.
Format: Artigo
Jezik:Inglês
Izdano: 2019
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8058781/
https://ncbi.nlm.nih.gov/pubmed/31707849
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/CIRCULATIONAHA.119.043805
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items